The REDEEM trial in patients with BPH used 0.5 mg of dutasteride, a 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone; a reduction in prostate volume and decreased PSA level were found. This evidence concerns the gene KLK3 and benign prostatic hyperplasia.